An announcement of a 5-year together led initiative by Medicines for Malaria Venture & PATH was made, VivAccess, for supporting the countries in eliminating the Plasmodium vivax (P. vivax) malaria. This initiative has a link with the larger international effort for supporting countries where malaria prevails permanently in the adoption of the latest methods and tools, to ease the effective radical treatment for preventing relapse of it. The work of VivAccess is funded by the renowned Bill and Melinda Gates Foundation. The main object of VivAccess is to support the increased access to the treatment products in order to address these challenges.
The Executive Vice President of Access and Product Management at MMV, George Jagoe passed the following statement: “Because one infection caused by the P. vivax parasite has the uncanny ability to cause a patient to relapse in the absence of a new infective mosquito bite, it amplifies the burden of malaria, placing a huge burden on the individuals, communities, and countries it infects. New tools to stop this cycle of the disease have been developed, and more are in development. VivAccess is set to accelerate their access to those in need and in doing so protect patients from relapses and support countries to move towards malaria elimination.”
Director of Malaria Control & Elimination at PATH Center, Doctor Larry Slutsker stated: “Relapsing malaria due to Plasmodium vivax is the most geographically widespread malaria, with well over 2 billion people living in areas of risk for infection. Vivax malaria causes massive suffering in terms of illness, anemia, and death. The new tools that we can now bring to bear through the VivAccess partnership present a unique opportunity to make progress against this major public health challenge and underscore the importance of continued investment in malaria research and development.”